NASDAQ$TYRA
Tyra Biosciences Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported positive interim clinical proof-of-concept results for TYRA-300, cleared IND for Phase 2 study of TYRA-300 in pediatric achondroplasia, strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer and held cash, cash equivalents, and marketable securities of $360.1 million.
Tyra Biosciences reported its Q3 2024 financial results, featuring positive interim data for TYRA-300 in mUC, progress in expanding TYRA-300 development into NMIBC, clearance for a Phase 2 achondroplasia study, and the appointment of Doug Warner as CMO. The company's cash reserves are expected to last through at least 2026.
- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study
- IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301)
- Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer
- Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024
Headline financials
Revenue & EPS history
Tyra Biosciences · Revenue · Quarterly
$0
Forward guidance
TYRA is focused on advancing its clinical programs and expects to dose the first child with achondroplasia in BEACH301 in Q1 2025 and submitting an IND for NMIBC by the end of this year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
+2.0%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+29.8%
Q3 2021
Best reaction
-11.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.5% | +7.7% | +21.8% | |
| Q3 2025 | +0.3% | +8.4% | +50.6% | |
| Q2 2025 | +0.4% | -4.3% | +17.0% | |
| Q1 2025 | -3.1% | -4.0% | +2.3% | |
| Q4 2024 | -0.8% | -10.5% | +3.9% | |
| Q3 2024 | -5.9% | -6.9% | -8.1% | |
| Q1 2024 | -3.8% | +3.1% | +9.7% | |
| Q4 2023 | +7.0% | +3.0% | -9.7% | |
| Q3 2023 | -6.3% | -8.1% | +2.5% | |
| Q2 2023 | +0.9% | +1.6% | -3.4% | |
| Q1 2023 | -3.3% | +7.0% | +13.1% | |
| Q4 2022 | -3.3% | +0.0% | -9.8% | |
| Q3 2022 | -7.1% | +12.9% | -3.1% | |
| Q2 2022 | +11.1% | +14.7% | -24.0% | |
| Q1 2022 | +0.1% | -5.9% | -17.8% | |
| Q4 2021 | -11.5% | -5.3% | -6.4% | |
| Q2 2021 | +29.8% | +20.3% | -26.6% | |
| Q3 2021 | +29.8% | +20.3% | -26.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro